Pascal Soriot and Larry Culp are prominent corporate leaders running two very different global companies: Soriot leads pharmaceutical group AstraZeneca, while Culp is chairman and CEO of GE Aerospace. There is no verified evidence of a direct business partnership, shared company role, or personal relationship between them, but their names have recently appeared together because both were included among Glassdoor’s highest-rated CEOs in the United States for 2026.
Their careers also overlap indirectly through the healthcare industry. Before leading GE, Culp spent years on the board of pharmaceutical company GlaxoSmithKline, while Soriot built most of his career in global pharmaceuticals before becoming AstraZeneca CEO.
Pascal Soriot and Larry Culp at a Glance
| Detail | Pascal Soriot | Larry Culp |
|---|---|---|
| Full name | Sir Pascal Soriot | H. Lawrence Culp Jr. |
| Current company | AstraZeneca | GE Aerospace |
| Current role | CEO and Executive Director | Chairman and CEO |
| Current CEO tenure | AstraZeneca CEO since October 2012 | GE Aerospace CEO since June 2022 |
| Core industry | Pharmaceuticals and biotechnology | Aerospace and aviation |
| Major earlier role | CEO of Genentech, COO of Roche Pharmaceuticals | CEO and President of Danaher |
| Education | Veterinary medicine, MBA from HEC Paris | Washington College, MBA from Harvard Business School |
| Notable outside role | Board member of Agilent Technologies | Non-executive chairman of GE HealthCare |
AstraZeneca continues to list Soriot as its CEO and a board member, a position he has held since October 2012. GE Aerospace identifies Culp as chairman and CEO, with Culp having become CEO of GE Aerospace in 2022 and chairman when the business became an independent public company in April 2024.
What Is the Connection Between Pascal Soriot and Larry Culp?
The most identifiable current connection between Pascal Soriot and Larry Culp is their inclusion in the Glassdoor Best CEOs 2026 list. Glassdoor placed Culp at No. 6 as CEO of GE Aerospace and Soriot at No. 9 as CEO of AstraZeneca.
Glassdoor says the 2026 list was based on U.S. employee feedback collected from May 16, 2025, through May 15, 2026. That means their appearance together reflects employee assessments of leadership at their respective employers rather than evidence of a commercial relationship between GE Aerospace and AstraZeneca.
No reliable public record reviewed for this article establishes that Soriot and Culp:
- have jointly operated a company
- serve together on the same corporate board
- have announced a personal investment partnership
- are related by family
- have participated in a disclosed AstraZeneca-GE Aerospace executive partnership
The distinction matters because searches combining the names of two senior executives can easily create the impression that they are connected through a deal or organization when the actual link is much narrower.
Why Their Careers Are More Connected Than They First Appear
Although Soriot and Culp currently work in separate industries, Culp has significant historical exposure to the pharmaceutical sector.
Larry Culp Served on the GlaxoSmithKline Board
Culp became a non-executive director of GlaxoSmithKline in July 2003 while serving as president and CEO of Danaher. Official GSK records show that he remained on the board until September 30, 2012.
That timing is notable because September 2012 was immediately before Soriot became CEO of AstraZeneca in October 2012. GSK and AstraZeneca were, and remain, major participants in the global pharmaceutical industry.
There is nevertheless no evidence that Culp’s GSK role represented a direct working relationship with Soriot. Soriot was working within Roche and Genentech before moving to AstraZeneca, not GSK.
Both Have Experience Across Healthcare Businesses
Culp’s best-known operating career developed at Danaher rather than inside a traditional pharmaceutical company. Danaher’s portfolio, however, included healthcare, life-science, diagnostics and applied technology businesses.
GE Aerospace’s biography of Culp states that he led Danaher as CEO and president from 2001 until 2014 after joining the organization in 1990. His current biography also records his previous GSK directorship.
Soriot’s career is much more directly concentrated in medicine and pharmaceuticals. AstraZeneca says he previously served as CEO of Genentech and chief operating officer of Roche’s pharmaceutical division before becoming AstraZeneca CEO.
As a result, both executives have significant experience managing complex science and technology businesses, but from different operational perspectives.
Who Is Pascal Soriot?
Sir Pascal Soriot is the longtime chief executive of AstraZeneca, the British-Swedish pharmaceutical company focused on prescription medicines.
AstraZeneca appointed him CEO in October 2012 after senior roles at Roche and Genentech. The company says he is trained as a Doctor of Veterinary Medicine and holds an MBA from HEC Paris.
His tenure has covered one of the most consequential periods in AstraZeneca’s modern history, including a major expansion of its oncology portfolio, investment in biologics and other therapeutic technologies, and the company’s involvement in developing a COVID-19 vaccine with the University of Oxford.
Soriot received a knighthood in 2022 for services to life sciences and leadership in the global response to the COVID-19 pandemic.
Soriot’s Current Role at AstraZeneca
As of September 2026, AstraZeneca continues to identify Pascal Soriot as its chief executive officer.
The company’s 2025 annual report showed total revenue of $58.7 billion, an increase of 9% at actual exchange rates, with 16 medicines reaching blockbuster status during the year. AstraZeneca is pursuing a stated ambition to reach $80 billion in annual total revenue by 2030.
The growth continued into 2026. AstraZeneca reported first-quarter revenue above $15 billion, up 8%, and said in July that first-half performance kept the company on track toward its 2030 target.
Soriot therefore remains directly associated with AstraZeneca’s long-term strategy rather than occupying a ceremonial leadership position.
Soriot’s Other Corporate Role
In May 2025, Agilent Technologies announced that Soriot had joined its board of directors. Agilent described him as bringing extensive pharmaceutical, biotechnology and healthcare leadership experience.
AstraZeneca also currently lists his outside appointments as including the boards of Agilent Technologies and Sustainable Markets Initiative Limited.
Who Is Larry Culp?
H. Lawrence “Larry” Culp Jr. is chairman and CEO of GE Aerospace, the aviation business that emerged from the restructuring of General Electric.
Culp became CEO of General Electric in October 2018 after joining the company’s board earlier that year. He subsequently became CEO of GE Aerospace in June 2022. When GE Aerospace became an independent public company in April 2024, he became its chairman and CEO.
Before GE, Culp built his reputation at Danaher, where he served as CEO and president between 2001 and 2014. He later worked as a senior lecturer at Harvard Business School and as a senior adviser to Bain Capital Private Equity.
Culp and the Restructuring of General Electric
Culp’s GE tenure is closely associated with the restructuring of the former General Electric conglomerate.
GE Aerospace states that during his leadership of GE, the company reduced debt by more than $100 billion and ultimately created three independent public companies:
- GE HealthCare
- GE Vernova
- GE Aerospace
GE Aerospace became the continuing publicly traded GE company following completion of the separation process in April 2024.
Culp then shifted from restructuring a diversified conglomerate to operating a focused aerospace company.
How GE Aerospace Is Performing Under Larry Culp
GE Aerospace’s recent results provide useful context for why Culp has remained prominent among major corporate CEOs.
For the second quarter of 2026, the company reported:
| Metric | Q2 2026 |
|---|---|
| Total orders | $16.5 billion |
| GAAP revenue | $13.3 billion |
| Adjusted revenue | $12.6 billion |
| GAAP profit | $2.8 billion |
| Free cash flow | $3.0 billion |
| Backlog | More than $210 billion |
GE Aerospace said GAAP revenue increased 21% compared with the prior-year period while adjusted revenue rose 24%. The company subsequently raised its full-year guidance.
Culp has emphasized the company’s proprietary FLIGHT DECK lean operating model, which focuses operational teams on safety, quality, delivery and cost. GE Aerospace’s 2025 annual report similarly described continuous operational improvement as central to its strategy.
The company’s activities span commercial engines, military propulsion, aviation systems and aftermarket services, placing Culp’s current operating environment far outside Soriot’s pharmaceutical field.
Also Read: Peter Woo and Larry Culp
Pascal Soriot and Larry Culp Have Different Leadership Challenges
The executives are often discussed in the broad context of corporate leadership, but the businesses they manage require substantially different forms of execution.
Soriot Manages Drug Development Risk
AstraZeneca must continually balance research spending, clinical trials, regulatory approvals, manufacturing and commercialization.
A promising drug can take years to develop and still fail during clinical testing. Patents also eventually expire, forcing pharmaceutical companies to continually replenish their pipelines.
AstraZeneca reported more than 100 Phase III studies underway as it entered 2026, illustrating the scale of the development portfolio under Soriot.
Culp Manages Manufacturing and Aviation Reliability
GE Aerospace faces a different set of pressures. It must manufacture sophisticated engines at scale, support an enormous installed fleet and maintain long-term relationships with airlines, aircraft manufacturers and defense customers.
Its Q2 2026 update emphasized engine deliveries, supplier output, maintenance shop capacity and durability improvements. GE Aerospace reported a 31% increase in total engine deliveries during the first half of 2026.
Aircraft engines may also remain in service for decades, meaning aftermarket maintenance and spare parts are strategically important parts of the business.
Their Leadership Styles Share an Emphasis on Operational Execution
There is no basis for claiming Soriot and Culp follow identical management philosophies. Their public records do, however, show a common emphasis on execution rather than leadership built entirely around financial engineering or branding.
Soriot’s AstraZeneca tenure has focused heavily on science, pipeline development, geographic expansion and turning research investment into commercially successful medicines.
Culp is strongly associated with lean management principles. GE Aerospace’s FLIGHT DECK operating model draws on continuous improvement methods familiar from his years at Danaher.
Both therefore operate businesses where sustained performance depends on thousands of smaller operational decisions rather than a single product or transaction.
The 2026 Glassdoor Recognition Explained
One of the clearest reasons internet users may encounter Pascal Soriot and Larry Culp together is Glassdoor’s 2026 CEO ranking.
Glassdoor listed:
- Larry Culp, GE Aerospace: No. 6
- Pascal Soriot, AstraZeneca: No. 9
The rankings were based on U.S. employee feedback submitted between May 16, 2025 and May 15, 2026.
That recognition does not measure company revenue, stock-market returns or personal wealth. It is based on Glassdoor’s employee-review methodology and should therefore be interpreted specifically as an employee-feedback ranking.
Being listed together is evidence of comparable recognition within that particular survey, not evidence of collaboration between the executives.
Larry Culp’s Pharmaceutical Connection Predates Soriot’s AstraZeneca Leadership
One of the more interesting chronological details is that Culp’s formal relationship with a large pharmaceutical company ended at almost exactly the time Soriot began leading AstraZeneca.
GSK announced that Culp stepped down as a director on September 30, 2012, after approximately nine years on its board.
AstraZeneca says Soriot became its CEO in October 2012.
The dates are close, but there is no evidence that one event caused or influenced the other. Culp was leaving a non-executive board position at GSK while Soriot was taking an executive position at a separate competing pharmaceutical business.
The overlap is useful mainly for understanding why Culp is not entirely unfamiliar with the governance of large healthcare companies.
How Their Previous Careers Compare
Pascal Soriot
Soriot’s career progression has largely remained within healthcare:
Veterinary training → pharmaceutical management → senior international positions → Genentech → Roche → AstraZeneca
His experience has therefore concentrated on pharmaceuticals, biotechnology and global healthcare markets.
Larry Culp
Culp’s route has been broader:
industrial management → Danaher executive leadership → corporate boards and academia → GE restructuring → GE Aerospace
His career has emphasized operating systems, portfolio management, manufacturing and organizational transformation.
The paths demonstrate two different routes into leadership of major science-based companies.
Are AstraZeneca and GE Aerospace Business Partners?
There is no major strategic partnership between AstraZeneca and GE Aerospace disclosed in the authoritative corporate sources reviewed for this article.
The two companies operate in fundamentally different markets. AstraZeneca researches, develops and commercializes prescription medicines, while GE Aerospace supplies aircraft engines, propulsion technologies and aviation systems.
Large multinational businesses can interact indirectly through suppliers, healthcare benefits, technology providers or institutional investors, but such routine corporate connections should not be interpreted as evidence of a Soriot-Culp partnership.
Are Pascal Soriot and Larry Culp Personally Connected?
No reliable public evidence establishes a notable personal relationship between Soriot and Culp.
They are both high-profile international executives and can therefore appear in the same leadership rankings, conferences, investor discussions or corporate-governance coverage. Their shared prominence is different from a verified personal friendship or private business association.
Claims of a closer relationship would require credible documentation before being treated as fact.
Their Positions as of 2026
As of September 2026, both executives remain in their respective leadership positions.
AstraZeneca’s latest leadership information continues to identify Soriot as CEO, and its July 27, 2026 half-year results were issued with comments from him in that role.
GE Aerospace likewise continues to identify Culp as chairman and CEO. He was quoted in the company’s July 16, 2026 second-quarter results and at the Farnborough International Airshow that month.
There is therefore no indication in the latest official information reviewed here that either leadership position has changed.
Executive Compensation Is Structured Differently
Direct comparisons between Soriot’s and Culp’s reported compensation can be misleading because AstraZeneca and GE Aerospace report executive pay under different accounting, regulatory and incentive frameworks.
GE Aerospace’s 2026 proxy statement reported $45.6 million in SEC total compensation for Culp for 2025. A large portion came from equity awards and stock options, and the company explicitly notes that accounting values assigned to stock awards do not necessarily equal the amount an executive ultimately receives.
That distinction is important when discussing executive wealth. Annual compensation disclosures are not the same thing as personal net worth, and neither executive’s true personal net worth can be established simply by adding publicly disclosed annual pay.
Why Pascal Soriot and Larry Culp Matter Beyond Their Companies
Soriot and Culp provide two examples of long-duration corporate leadership in sectors where execution is unusually complicated.
Soriot must manage a business dependent on scientific discovery, clinical evidence, regulatory decisions and global healthcare systems. Culp operates a company whose products require extraordinarily high reliability while depending on global manufacturing and aerospace supply chains.
Both leaders have also remained associated with major organizational transformations.
For AstraZeneca, Soriot’s tenure has coincided with the company’s development into a larger oncology and specialty-medicine business with an ambitious 2030 growth target.
For Culp, the defining transformation was restructuring General Electric and moving its remaining aerospace operation into an independent GE Aerospace.
Those similarities help explain why their names can appear in the same discussions about corporate leadership even when their industries rarely intersect directly.
FAQ About Pascal Soriot and Larry Culp
Are Pascal Soriot and Larry Culp business partners?
No verified evidence shows that Pascal Soriot and Larry Culp are business partners. Soriot runs AstraZeneca and Culp runs GE Aerospace, and no significant joint enterprise between the two executives is disclosed in the authoritative sources reviewed for this article.
Why are Pascal Soriot and Larry Culp mentioned together?
One current reason is the Glassdoor Best CEOs 2026 list. Larry Culp was ranked No. 6 and Pascal Soriot No. 9 based on U.S. employee feedback collected during the ranking’s eligibility period.
Did Larry Culp work in the pharmaceutical industry?
Culp’s primary executive career was not in pharmaceuticals, but he served as a non-executive director of GlaxoSmithKline from July 2003 until September 2012.
Is Pascal Soriot still CEO of AstraZeneca?
Yes. AstraZeneca continued to identify Pascal Soriot as CEO in its official leadership information and July 2026 financial results.
Is Larry Culp still CEO of GE Aerospace?
Yes. GE Aerospace’s current leadership information identifies H. Lawrence Culp Jr. as chairman and CEO, and he remained in the role during the company’s July 2026 second-quarter reporting.
Do Pascal Soriot and Larry Culp serve on the same board?
No current shared board membership was identified. Soriot serves on AstraZeneca’s board and is also an Agilent Technologies director, while Culp chairs GE Aerospace and serves as non-executive chairman of GE HealthCare.
Also Read: Heidi Capozzi and Larry Culp
